Shopping Cart 0
Cart Subtotal
USD 0

Zynerba Pharmaceuticals Inc (ZYNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company provides pipeline product candidates such as ZYN002 and ZYN001. Its ZYN002 is a synthetic CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals's ZYN001 is a pro-drug of THC which enables the transdermal delivery through skin and into the circulatory system via patch. The company's pipeline candidates target various indications which include refractory focal epilepsy, fragile x syndrome, developmental and epileptic encephalopathies, fibromyalgia and peripheral neuropathic pain, among others. Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, the US.

Zynerba Pharmaceuticals Inc (ZYNE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Zynerba Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Zynerba Pharma Raises USD13 Million in Venture Financing 11

Partnerships 12

Zynerba Pharma Partners with Lohmann Therapie-Systeme 12

Licensing Agreements 13

Zynerba Pharma Enters into Patent Assignment Agreement with Albany College of Pharmacy 13

Equity Offering 14

Zynerba Pharma Prices Public Offering of Shares for USD32.5 Million 14

Zynerba Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 16

Zynerba Pharma Raises USD48.3 Million in IPO 18

Zynerba Pharmaceuticals Inc-Key Competitors 20

Zynerba Pharmaceuticals Inc-Key Employees 21

Zynerba Pharmaceuticals Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Aug 02, 2018: Zynerba Pharmaceuticals reports second quarter 2018 financial results and operational highlights 23

May 08, 2018: Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights 25

Mar 12, 2018: Zynerba Pharmaceuticals Announces Fourth Quarter and Year End 2017 Financial Results 27

Nov 14, 2017: Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights 29

Aug 01, 2017: Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights 32

May 09, 2017: Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights 34

Mar 27, 2017: Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights 36

Corporate Communications 38

Apr 16, 2018: Zynerba Pharmaceuticals Names John P. Butler To Board of Directors 38

Jan 03, 2018: Zynerba Pharmaceuticals announces Appointment of new Chief Medical Officer 39

Clinical Trials 40

Jan 03, 2017: Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Zynerba Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Zynerba Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Zynerba Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Zynerba Pharma Raises USD13 Million in Venture Financing 11

Zynerba Pharma Partners with Lohmann Therapie-Systeme 12

Zynerba Pharma Enters into Patent Assignment Agreement with Albany College of Pharmacy 13

Zynerba Pharma Prices Public Offering of Shares for USD32.5 Million 14

Zynerba Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 16

Zynerba Pharma Raises USD48.3 Million in IPO 18

Zynerba Pharmaceuticals Inc, Key Competitors 20

Zynerba Pharmaceuticals Inc, Key Employees 21

Zynerba Pharmaceuticals Inc, Subsidiaries 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Zynerba Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.